InvestingDaily.com

Account Information

  • My Account

    Manage all your subscriptions, update your address, email preferences and change your password.

  • Help Center

    Get answers to common service questions, ask the analyst or contact our customer service department.

  • My Stock Talk Profile

    Update your stock talk name and/or picture.



Close
FEATURED STRATEGY

$1,230 in Instant Income?

$1,230 in Instant Income?Our top income expert recently pulled the wraps off his breakthrough moneymaking technique. And he proved beyond a shadow of a doubt how you can use it to generate instant cash payouts of up to $1,230 (or more). Over and over again. But then he took things a big step further and guaranteed you can make $1 million by following his program. And the second he did, our phones went nuts! Space is limited — get the details here.

 

 

Ignore The Hype! How to Pick a Mutual Fund Manager

By John Persinos on December 22, 2016

Too many mutual fund managers seem to follow one purpose: transferring wealth from their clients to their trading desks. I’m reminded of this fact by a recent letter from a reader:

I want to start putting my money in a mutual fund, but how do I pick the right fund manager? How can I sort through the marketing hype and figure out if the fund management is any good or not? — Bill C.

If you’re looking for the best mutual funds for your money in 2017, you first need to look at the quality of the fund’s management. That means sorting through the marketing hype and taking a no-nonsense look at the fund’s prospectus. Below, I show you how.

Evaluate Past Performance

Performing due diligence is vital to hiring the appropriate fund manager. To find the fund manager that best fits your needs, carefully examine the fund’s prospectus to evaluate:

  • Variability and consistency of returns;
  • Absolute returns, past returns, and returns on a risk-adjusted basis:
  • Performance in the context of the fund’s asset class and in the context of its peer group;
  • Performance relative to the appropriate benchmarks, including the up and down market-capture ratio (how much of the positive/negative rates of returns the portfolio manager is capturing);
  • Amount of assets under management and the amount of time (in years) required to rack up a positive track record; 
  • The consolidated asset size (not the individual transactions fees).

I want to elaborate on this last point because it’s often overlooked. Instead of fixating on individual transactions fees, look at the negotiated assets-based fee, which should cover portfolio management fees, trading costs, custodial fees, investment management consulting, and any other operating expenses.

Management compensation should be largely comprised of performance-based fees, so your interests and the manager’s interests are closely aligned.

Monitor Ongoing Performance

Don’t hand over control of your portfolio and then put it on automatic pilot. You should never be passive about the management of your wealth, even if you’re paying someone else to manage it for you.

Be sure to perform regular performance reviews of your portfolio and take care to place performance in the wider context of your long-term policies as well as the overall market conditions. Your manager should make all underlying investment activity available to you.

To evaluate manager performance, consider:

  • What were the market conditions during the performance review period?
  • Did the tangible results meet your expressed goals?
  • How much risk did the manager shoulder to reach those results? Are you comfortable with this risk level? Was the risk too low, or too high?
  • Are you moving closer to your objectives or drifting further away?

Insist on transparency of trades, so you can measure performance not just in terms of gains or losses but also in terms of returns and risk. Transparency provides the groundwork for you to evaluate manager performance and compare it to your investment strategy.

Reporting of performance should be on both a composite basis and on an individual manager basis. Reporting also should allow for varying levels of analysis along each asset class and each asset style, and on a gross- and net-of-fee basis.

Calculate your returns on both a time-weighted and dollar-weighted basis. The time-weighted rate of return is a superb method to evaluate the money manager’s performance because it minimizes the effects of cash flows. Dollar-weighted rates-of-return measure the portfolio’s total growth.

Weapons of wealth destruction…

insert artwork

Deon Vernooy, chief investment strategist of our publication Canadian Edge, offers this warning about mutual funds, coupled with advice:

“Mutual-fund fees never reached the extremes of hedge funds or private equity funds. But they still manage to charge rich fees linked to the value of the assets under management.

As markets generally rise over time, so do fund assets. As a result, managers earn more without having to do any more work. Our suggestion is simply that investors should be acutely aware of visible and hidden fees included in the funds or other products used to construct their long term investment portfolios.”

Tornado in a trailer park…

I received this letter from a reader, in response to my article yesterday about sectors that will be “yuge” under a Trump administration:

“Few sectors made very much year to date. Technology and small caps rose, but Big Pharma and biotechs suffered. Year to date, the iShares Nasdaq Biotechnology ETF (NSDQ: IBB) is down 20.8% and the SPDR S&P Biotech ETF (NYSE: XBI) is down 13.8%.

I do not understand this at all. My question to you is if you see a possibility that the prices of IBB and XBI will go much higher in the coming months or the present situation will continue without serious change.” — Yair S.

It’s true, biotech short sellers have been having more fun than a tornado in a trailer park. Much of the pessimism stems from worries that the president-elect and Congress will put pressure on drug companies to lower prices, but I think that fear is overblown.

When the political pandering subsides, the drug industry will remain unscathed under a deregulation-minded Trump administration. Several solid biotech companies enjoy robust product pipelines, while populations around the world are getting older and sicker. The biotech sector is home to several undervalued gems right now; I think IBB and XBI are poised to go higher next year.

Got a question? Drop me a line: mailbag@investingdaily.com — John Persinos

Editor’s Note: As I mentioned yesterday, Jim Pearce and his MIT-trained partner are still accepting applications for anyone who wants to use their proven algorithmic trading approach in 2017. It’s called the Rapid Profits Matrix system, and I’ve been told that applications will be accepted until midnight tomorrow. If you miss out, don’t say I didn’t warn you! Click here now for more details from Jim

 

 

 


You might also enjoy…

 

12 Stocks Virtually Guaranteed to Go Up in 2018

You may not believe it, but I have a calendar in my hands right now that tells me the exact date and time when a few stock are practically guaranteed to go up. 

Twelve of them, in fact.

And if you were to invest in them following the simple buy and sell instructions found in this calendar…

You could be making $1,181… $11,814…. and as much as $190,916 more than by using a “buy-and-hold” strategy.

And here’s the best part…

I’m giving away a few copies of this calendar to interested investors (First come, first served).

With this calendar, you could get higher profits with less risk.

Click here to get the full story, and to claim your copy.

Stock Talk — Post a comment Comment Guidelines

Our Stock Talk section is reserved for productive dialogue pertaining to the content and portfolio recommendations of this service. We reserve the right to remove any comments we feel do not benefit other readers. If you have a general investment comment not related to this article, please post to our Stock Talk page. If you have a personal question about your subscription or need technical help, please contact our customer service team. And if you have any success stories to share with our analysts, they’re always happy to hear them. Note that we may use your kind words in our promotional materials. Thank you.

You must be logged in to post to Stock Talk OR create an account.

Create a new Investing Daily account

  • - OR -

* Investing Daily will use any information you provide in a manner consistent with our Privacy Policy. Your email address is used for account verification and will remain private.